ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $982,000 | -30.5% | 27,551 | -10.0% | 0.00% | -33.3% |
| Q2 2023 | $1,412,000 | -36.4% | 30,602 | -44.7% | 0.01% | -33.3% |
| Q1 2023 | $2,219,000 | -15.0% | 55,345 | -1.8% | 0.01% | -18.2% |
| Q4 2022 | $2,612,000 | +66.7% | 56,376 | +48.9% | 0.01% | +57.1% |
| Q3 2022 | $1,567,000 | -21.0% | 37,851 | +13.8% | 0.01% | -12.5% |
| Q2 2022 | $1,984,000 | -24.2% | 33,247 | -7.7% | 0.01% | -11.1% |
| Q1 2022 | $2,616,000 | -16.5% | 36,023 | -3.3% | 0.01% | -18.2% |
| Q4 2021 | $3,133,000 | -8.6% | 37,252 | -1.9% | 0.01% | -8.3% |
| Q3 2021 | $3,426,000 | -6.1% | 37,986 | -0.8% | 0.01% | -7.7% |
| Q2 2021 | $3,650,000 | +2544.9% | 38,276 | +3063.3% | 0.01% | +1200.0% |
| Q1 2021 | $138,000 | -17.9% | 1,210 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $168,000 | +50.0% | 1,210 | -11.5% | 0.00% | 0.0% |
| Q3 2020 | $112,000 | – | 1,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |